ClinicalTrials.gg
CompletedNCT04340362Updated Sep 24, 2025Results posted

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

A Phase 2 interventional study of VX-147 in Glomerulosclerosis, Focal Segmental, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 44 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States — 18 open to participants now, 21 under way, 2 of them phase 3. Glomerulosclerosis, Focal Segmental · United States.

Enrollment
40th of 56
16 · median 30
Started
2020
with 2 others
Phase 2
29 of 69
4 open now
Registered
44th of 69
by date
Lead sponsor
3 of 69
Vertex Pharmaceuticals Incorporated

Among the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, this one is the 40th largest by enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2020, is one of 29 in phase 2, and was the 44th registered.

Glomerulosclerosis, Focal Segmental

106 studies on the registry are indexed under Glomerulosclerosis, Focal Segmental; 34 are open to participants now.

Browse Glomerulosclerosis, Focal Segmental studies →

Open to participants now

18 of the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Glomerulosclerosis, Focal Segmental studies recruiting now, 11 (35%) set no upper age limit and 13 (42%) stop at 75 or younger; 23 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).

03

Conditions studied

  • Glomerulosclerosis, Focal Segmental
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • APOL1 genotype of G1/G1, G2/G2, or G1/G2
  • FSGS diagnosed by kidney

Key Exclusion Criteria:

  • Evidence of non-APOL1-mediated FSGS
  • Participants with known sickle cell disease
  • Solid organ or Bone marrow transplant

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    VX-147

    All participants received VX-147 at a dosage of 15 mg once daily (qd) for 2 weeks and VX-147 at a dosage of 45 mg qd for 11 weeks. Part A was enrolled in 2 cohorts: Cohort 1 and Cohort 2. Cohort 1 included participants with urine protein to creatinine ratio (UPCR) approximately greater than or equal to (≥) 3 g/g (± 10%) and less than (\<) 10 g/g and estimated glomerular filtration rate (eGFR) approximately ≥30 mL/min/1.73 m2 (± 10%). Cohort 2 included participants with UPCR approximately ≥0.8 g/g (± 10%) and \<2.7 g/g and eGFR approximately ≥30 mL/min/1.73 m2.

    Drug: VX-147

Interventions

  • DrugVX-147

    Tablets for oral administration.

    Also known as: IXP

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in UPCR

    Time frame: From Baseline up to Week 13

Secondary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From Baseline up to Week 17

  2. Maximum Observed Concentration (Cmax) of VX-147

    Time frame: Pre-dose and at 0.25, 0.5, 1, 2, 4, and 12 hours post-dose on Day 1 and Week 5

  3. Observed Pre-dose Concentration (Ctrough) of VX-147

    Time frame: Pre-dose on Day 8, 15, Week 3, 5, 9 and 13

  4. Area Under the Concentration Time-curve From 0 to 24 Hours (AUC0-24hr) of VX-147

    Time frame: Pre-dose and at 0.25, 0.5, 1, 2, 4, 12 and 24 hours Post-dose on Week 5

07

Results

Posted Jul 10, 2023

Participant flow

This study was planned in 2 parts: Part A (Treatment Period), which consisted of 2 cohorts (i.e., cohort 1 and 2) and Part B (Optional Exploratory Off-treatment Follow-up Period). The primary and secondary efficacy analyses and safety analyses were planned for only Part A.

Participant flow — Overall Study
MilestoneVX-147
Started16
Cohort 13
Cohort 213
Completed15
Not completed1
Withdrew: Withdrawal of consent (not due to adverse event)1

Outcome measures

PrimaryPercent Change From Baseline in UPCR
Time frame:
From Baseline up to Week 13
Reported as:
Geometric mean · percent change
Percent Change From Baseline in UPCR
percent changeVX-147
Cohort 1-47.7 (-70.1 to -8.5)
Cohort 2-47.5 (-63.4 to -24.6)
Total-47.6 (-60.0 to -31.3)
SecondarySafety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
From Baseline up to Week 17
Reported as:
Count of participants · Participants
Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsVX-147
Cohort 1: Participants With TEAEs3
Cohort 1: Participants With SAEs0
Cohort 2: Participants With TEAEs12
Cohort 2: Participants With SAEs1
SecondaryMaximum Observed Concentration (Cmax) of VX-147
Time frame:
Pre-dose and at 0.25, 0.5, 1, 2, 4, and 12 hours post-dose on Day 1 and Week 5
Reported as:
Mean · micrograms per milliliter (mcg/ml)
Maximum Observed Concentration (Cmax) of VX-147
micrograms per milliliter (mcg/ml)VX-147
15 mg qd: Day 10.168 ± 0.0630
45 mg qd: Week 50.846 ± 0.303
SecondaryObserved Pre-dose Concentration (Ctrough) of VX-147
Time frame:
Pre-dose on Day 8, 15, Week 3, 5, 9 and 13
Reported as:
Mean · mcg/ml
Observed Pre-dose Concentration (Ctrough) of VX-147
mcg/mlVX-147
15 mg qd: Day 80.153 ± 0.0984
15 mg qd: Day 150.123 ± 0.0796
45 mg qd: Week 30.379 ± 0.249
45 mg qd: Week 50.492 ± 0.265
45 mg qd: Week 90.446 ± 0.342
45 mg qd: Week 130.529 ± 0.302
SecondaryArea Under the Concentration Time-curve From 0 to 24 Hours (AUC0-24hr) of VX-147
Time frame:
Pre-dose and at 0.25, 0.5, 1, 2, 4, 12 and 24 hours Post-dose on Week 5
Reported as:
Mean · hour*mcg/mL (h*mcg/mL)
Area Under the Concentration Time-curve From 0 to 24 Hours (AUC0-24hr) of VX-147
hour*mcg/mL (h*mcg/mL)VX-147
Area Under the Concentration Time-curve From 0 to 24 Hours (AUC0-24hr) of VX-14715.3 ± 6.37

Adverse events

Collected over Day 1 up to Week 17. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VX-147 : Cohort 10/3 (0%)0/3 (0%)3/3 (100%)
VX-147: Cohort 20/13 (0%)1/13 (7.7%)12/13 (92.3%)
VX-147 Total0/16 (0%)1/16 (6.3%)15/16 (93.8%)
Most frequent serious events
Most frequent serious events
EventVX-147 : Cohort 1VX-147: Cohort 2VX-147 Total
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/31/131/16
Deep vein thrombosisVascular disorders0/31/131/16
Most frequent other events
Showing 10 of 37
Most frequent other events
EventVX-147 : Cohort 1VX-147: Cohort 2VX-147 Total
Abdominal painGastrointestinal disorders1/30/131/16
DiarrhoeaGastrointestinal disorders1/31/132/16
NauseaGastrointestinal disorders1/32/133/16
VomitingGastrointestinal disorders1/30/131/16
Tinea pedisInfections and infestations1/30/131/16
Electrocardiogram ST segment depressionInvestigations1/30/131/16
HeadacheNervous system disorders1/33/134/16
EpistaxisRespiratory, thoracic and mediastinal disorders1/30/131/16
Decubitus ulcerSkin and subcutaneous tissue disorders1/30/131/16
Back painMusculoskeletal and connective tissue disorders0/33/133/16

Baseline characteristics

All participants who received at least one dose of the study drug during the treatment period were included in the baseline analysis.

Age, Continuous
Age, Continuous(years)VX-147
Cohort 145.0 ± 10.5
Cohort 237.3 ± 15.2
Sex: Female, Male
Sex: Female, Male(Participants)VX-147
Cohort 1 — Female2
Cohort 1 — Male1
Cohort 2 — Female7
Cohort 2 — Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VX-147
Cohort 1 — Hispanic or Latino0
Cohort 1 — Not Hispanic or Latino3
Cohort 1 — Unknown or Not Reported0
Cohort 2 — Hispanic or Latino0
Cohort 2 — Not Hispanic or Latino13
Cohort 2 — Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VX-147
Cohort 1 — American Indian or Alaska Native0
Cohort 1 — Asian0
Cohort 1 — Native Hawaiian or Other Pacific Islander0
Cohort 1 — Black or African American3
Cohort 1 — White0
Cohort 1 — More than one race0
Cohort 1 — Unknown or Not Reported0
Cohort 2 — American Indian or Alaska Native0
Cohort 2 — Asian0
Cohort 2 — Native Hawaiian or Other Pacific Islander0
Cohort 2 — Black or African American13
Cohort 2 — White0
Cohort 2 — More than one race0
Cohort 2 — Unknown or Not Reported0
Urine Protein to Creatinine Ratio (UPCR)
Urine Protein to Creatinine Ratio (UPCR)(g/g)VX-147
Cohort 13.47 ± 1.07
Cohort 21.77 ± 0.49
08

Study locations

44 sites
  • University of Alabama at Birmingham - The Kirklin Clinic
    Birmingham, Alabama 35294, United States
  • California Institute of Renal Research
    San Diego, California 92123, United States
  • The George Washington University Medical Faculty Associates - Kidney Disease & Hypertension
    Washington D.C., District of Columbia 20037, United States
  • Howard University Hospital
    Washington D.C., District of Columbia 20060, United States
  • Kidney and Hypertension Specialists of Miami
    Miami, Florida 33150, United States
  • Florida Premier Research Institute
    Winter Park, Florida 32789, United States
  • Morehouse School of Medicine, Grady Memorial Hospital
    Atlanta, Georgia 30310, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30329, United States
  • Georgia Nehphrology
    Lawrenceville, Georgia 30046, United States
  • Central Georgia Kidney Specialists PC
    Macon, Georgia 31201, United States
  • Renal Associates of Baton Rouge
    Baton Rouge, Louisiana 70808, United States
  • Ochsner Medical Center - New Orleans
    New Orleans, Louisiana 70121, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Renal and Transplant Associates of New England, PC
    Springfield, Massachusetts 01107, United States
  • Paragon Health, PC d/b/a Nephrology Center, PC
    Kalamazoo, Michigan 49007, United States
  • Nephrology and Hypertension Associates, LTD
    Tupelo, Mississippi 38801, United States
  • St Louis Kidney Care
    St Louis, Missouri 63136, United States
  • Nevada Kidney Disease and Hypertension Centers
    Las Vegas, Nevada 89106, United States
  • SUNY Downstate
    Brooklyn, New York 11203, United States
  • Urban Family Practice
    Buffalo, New York 14201, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • UNC Kidney Center Division of Nephrology & Hypertension
    Chapel Hill, North Carolina 27599, United States
  • Tryon Medical Partners
    Charlotte, North Carolina 28210, United States
  • Durham Nephrology Associates, PA
    Durham, North Carolina 27704, United States
  • Duke University School of Medicine - Duke Molecular Physiology Institute
    Durham, North Carolina 27710, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • South Carolina Nephrology and Hypertension Center, Inc.
    Orangeburg, South Carolina 29118, United States
  • Vanderbilt University VU
    Nashville, Tennessee 37232, United States
  • Prolato Clinical Research Center
    Houston, Texas 77054, United States
  • Privia Medical Group
    Houston, Texas 77095, United States
  • Hopital Henri Mondor
    Créteil, France
  • Hôpital Bicêtre AP-HP
    Le Kremlin-Bicêtre, France
  • Bichat Hospital
    Paris, France
  • Hopitaux Universitaires Est Parisien - Hopital Tenon
    Paris, France
  • Service de Nephrologie - Hopital Universitaire Necker
    Paris, France
  • Université Paris-Descartes / Hôpital Européen Georges Pompidou
    Paris, France
  • GCM Medical Group, PSC
    San Juan, 00917, Puerto Rico
  • University Hospitals of Leicester NHS Trust - Leicester General Hospital
    Leicester, United Kingdom
  • Barts Health NHS Trust
    London, United Kingdom
  • The Medicines Evaluation Unit
    Manchester, United Kingdom
  • King's College Hospital NHS Foundation Trust - Guthrie Clinic
    Southwark, United Kingdom
09

References and documents

Publications

  • Egbuna O, Zimmerman B, Manos G, Fortier A, Chirieac MC, Dakin LA, Friedman DJ, Bramham K, Campbell K, Knebelmann B, Barisoni L, Falk RJ, Gipson DS, Lipkowitz MS, Ojo A, Bunnage ME, Pollak MR, Altshuler D, Chertow GM; VX19-147-101 Study Group. Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. N Engl J Med. 2023 Mar 16;388(11):969-979. doi: 10.1056/NEJMoa2202396. PubMed 36920755 ↗
  • Bruggeman LA, Sedor JR, O'Toole JF. Apolipoprotein L1 and mechanisms of kidney disease susceptibility. Curr Opin Nephrol Hypertens. 2021 May 1;30(3):317-323. doi: 10.1097/MNH.0000000000000704. PubMed 33767059 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent research/clinical-trial-data-sharing.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Nov 2021, 17 months.

Results were first posted in Jul 2023, 1 year 7 months after primary completion. A results delay was requested in Nov 2022.

Of 17 phase 2 interventional studies under Glomerulosclerosis, Focal Segmental, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 42. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2020
First posted
Apr 9, 2020
StartActual
Jun 8, 2020
Primary completionActual
Nov 11, 2021
CompletionActual
Dec 9, 2021
Results delay requested
Nov 10, 2022
Results first posted
Jul 10, 2023
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04340362
Responsible party
Sponsor
First posted
Apr 9, 2020
Start date
Jun 8, 2020
Primary completion
Nov 11, 2021
Completion
Dec 9, 2021
Results posted
Jul 10, 2023
Last update
Sep 24, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inaxaplin

Start the discussion